Overview

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (RESOLVE)

Status:
Not yet recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

Summary

The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult RA patients with an inadequate response to MTX alone.

Phase:

Phase 2

Details

Lead Sponsor:

SynAct Pharma Aps

Collaborator:

NBCD A/S